According to the latest data from the Hong Kong Stock Exchange, on December 31st, Board Chairman Wu Yifang increased his stake in Everest Medicines (01952) by purchasing 30,000 shares at a price of HK$37.98 per share, amounting to a total investment of HK$1.1394 million.
Following this acquisition, his total shareholding has risen to approximately 2.0747 million shares, representing a 0.59% stake in the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments